Physician profile
Alan N Yager
NPI 1306941216
$6,037.62
in general payments reported to CMS, 2019-2025
29 companies · $489 in 2025
The $489 reported for 2025 was more than what 76% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $1,172 · 2021: $1,071 · 2022: $901 · 2023: $651 · 2024: $557 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,696.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,196.17 | 2019-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $959.69 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $643.17 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $613.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $445.93 | 2019-2023 | |
| Lilly USA, LLC | $384.15 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $352.63 | 2019-2025 | Evenity, Repatha, Otezla |
| Amarin Pharma, INC. | $228.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $205.91 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $158.44 | 2021-2024 | |
| Pfizer INC. | $111.00 | 2020-2024 | |
| Astellas Pharma US INC | $71.15 | 2022-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $53.99 | 2021-2025 | Freestyle Libre |
| Phathom Pharmaceuticals, INC. | $52.98 | 2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $45.20 | 2019-2020 | |
| Exact Sciences Corporation | $41.70 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $40.15 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.08 | 2021-2023 | Relistor |
| Currax Pharmaceuticals LLC | $32.15 | 2022-2023 | Contrave, Onzetra Xsail |
| Edwards Lifesciences Corporation | $28.93 | 2024 | |
| Medtronic, INC. | $25.33 | 2025 | Minimed 780g |
| Insulet Corporation | $22.28 | 2025 | Omnipod |
| Mylan Specialty L.P. | $18.49 | 2021 | |
| Dexcom, INC. | $18.43 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $16.02 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.82 | 2022 | |
| Circassia INC. | $15.09 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.66 | 2024 | Rytary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Yager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.